Oxycodone — research review 2

...and oxycodone, a semisynthetic μ-agonist, is frequently prescribed for pain. But when we look at the evidence on long-term use, there are important questions about its impact on biological aging and all-cause mortality.

Exactly. While pain relief is crucial – and untreated pain itself can accelerate biological aging, as shown with diabetic neuropathy and epigenetic aging in GeroScience 2025 – we also have data suggesting risks with long-term opioid use.

Right. A study in Public Health 2024 found chronic opioid use was associated with a higher risk of all-cause mortality compared to short-term use, with a hazard ratio of 1.37. That's a significant finding.

And the picture gets more complex when other medications are involved. For instance, combining oxycodone with gabapentinoids, often prescribed for neuropathic pain, showed an increased risk of CNS depression and mortality – an odds ratio of 2.76 – in research published in Frontiers in Pharmacology 2022.

So, it highlights the need to weigh the benefits of pain relief, which can prevent pain's negative impact on aging, against these documented long-term risks.

Absolutely. For individuals genuinely benefiting from supervised short-term use, these are important considerations for their healthcare providers. What's still uncertain, though, is the direct mechanism by which long-term oxycodone use might influence biological aging markers, beyond the observed mortality associations and known risks like falls or sedation. More research is needed there.